Taiwan - Delayed Quote TWD

SciVision Biotech Inc. (1786.TW)

Compare
96.20
-0.10
(-0.10%)
At close: December 27 at 1:30:19 PM GMT+8
Loading Chart for 1786.TW
DELL
  • Previous Close 96.30
  • Open 97.50
  • Bid 96.10 x --
  • Ask 96.20 x --
  • Day's Range 96.20 - 99.50
  • 52 Week Range 73.20 - 144.00
  • Volume 844,247
  • Avg. Volume 660,806
  • Market Cap (intraday) 6.906B
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) 32.61
  • EPS (TTM) 2.95
  • Earnings Date --
  • Forward Dividend & Yield 2.53 (2.39%)
  • Ex-Dividend Date Jul 26, 2024
  • 1y Target Est 153.00

SciVision Biotech Inc. engages in the production and sale of hyaluronic acid medical products in Taiwan and internationally. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It is also involved in the wholesale of medical equipment; and provides management consulting services. The company was founded in 1990 and is based in Kaohsiung, Taiwan.

www.scivision.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1786.TW

View More

Performance Overview: 1786.TW

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

1786.TW
26.77%
TSEC CAPITALIZATION WEIGHTED ST
29.81%

1-Year Return

1786.TW
26.44%
TSEC CAPITALIZATION WEIGHTED ST
31.12%

3-Year Return

1786.TW
109.98%
TSEC CAPITALIZATION WEIGHTED ST
29.59%

5-Year Return

1786.TW
71.44%
TSEC CAPITALIZATION WEIGHTED ST
93.95%

Compare To: 1786.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1786.TW

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    6.91B

  • Enterprise Value

    6.28B

  • Trailing P/E

    32.61

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.73

  • Price/Book (mrq)

    3.79

  • Enterprise Value/Revenue

    7.56

  • Enterprise Value/EBITDA

    18.96

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.18%

  • Return on Assets (ttm)

    6.41%

  • Return on Equity (ttm)

    13.31%

  • Revenue (ttm)

    815.25M

  • Net Income Avi to Common (ttm)

    213.44M

  • Diluted EPS (ttm)

    2.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    861.28M

  • Total Debt/Equity (mrq)

    13.53%

  • Levered Free Cash Flow (ttm)

    227.46M

Research Analysis: 1786.TW

View More

People Also Watch